Navigation Links
Spitfire Pharma, Inc. will present body weight, liver weight and glucose regulation data on the GLP-1/Glucagon Dual Agonist SP-1373 at the American Diabetes Association's 77th Scientific Sessions
Date:4/11/2017

SOUTH SAN FRANCISCO, Calif., April 11, 2017 /PRNewswire/ -- Spitfire Pharma, Inc., ("Spitfire") is pleased to announce that research concerning their novel dual acting oxyntomodulin-based drug candidate SP-1373, has been selected for presentation at the American Diabetes Association's 77th Scientific Sessions. (Sunday Jun 11, 2017 12:00 PM - 1:00 PM, Poster 322-LB in category 22-A, Obesity-Animal)

"Type 2 diabetes, obesity and non-alcoholic steatohepatitis are major medical problems that are still in need of additional therapeutics. Spitfire Pharma LLC has been interested in harnessing the beneficial effects of the body's natural dual acting hormone oxyntomodulin (GLP-1/glucagon dual receptor agonist). A successful drug of this nature could add to the toolkit of physicians caring for such patients," said Dr. Andrew J. Perlman, Spitfire's Chief Medical Officer.

About Spitfire Pharma, Inc. 
Spitfire Pharma, Inc., is a "virtual" company which was created to hold the ownership of the SP-1373 development program. Spitfire is funded by Velocity Pharmaceutical Holdings, LLC (VPD). The SP-1373 development program is managed under contract by VPD. 

About Velocity Pharmaceutical Development, LLC 
VPD is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. VPD then manages a development program for each drug candidate intended to generate convincing human proof of concept data (generally by conducting a phase 2 clinical trial). Following successful human proof of concept, VPD then seeks a large pharmaceutical company acquirer for each program. VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials. This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures. VPD believes this new capital-efficient model will yield attractive new drugs to treat patients with significant unmet clinical needs. The company is located in South San Francisco, California. More information is available at www.vpd.net

About Velocity Pharmaceutical Holdings, LLC 
Velocity Pharmaceutical Holdings, LLC, is an entity funded by Presidio Partners that makes investments in highly virtual, project-focused pharmaceutical development companies that are managed by Velocity Pharmaceutical Development, LLC. More information is available at www.vpd.net and www.presidiopartners.com

Contact
Leslie Loven
1-415-524-7326
leslie@vpd.net

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spitfire-pharma-inc-will-present-body-weight-liver-weight-and-glucose-regulation-data-on-the-glp-1glucagon-dual-agonist-sp-1373-at-the-american-diabetes-associations-77th-scientific-sessions-300437782.html


'/>"/>
SOURCE Spitfire Pharma, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. NovoBioPharma, Partnership of Top Life Science Experts, Launches
2. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
3. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
4. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
5. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
6. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of ViroPharma, Inc. - VPHM
8. Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana
9. Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
10. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
11. Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
Breaking Medicine News(10 mins):